TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33515745
Drug: Gore-Tex suture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gore-Tex suture (2-0 Gore-Tex; W. L. Gore & Associates, Inc.)
Study: 32759543
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy with 10 mg/day rosuvastatin plus 1,800 mg/day eicosapentaenoic acid (EPA)
Study: 32759543
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with 2.5 mg/day rosuvastatin
Study: 32812652
Drug: PIEB +
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIEB + PCEA (5 ml bolus every hour, 5 ml PCEA bolus lockout 20 minutes)
Study: 32812652
Drug: CEI +
Normalized name: Ceiba pentandra fiber
DrugBank: Ceiba pentandra fiber (DB10411)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEI + PCEA (5 ml/h, 5 ml PCEA bolus, lockout 20 minutes)
Study: 33772508
Drug: Ketogenic diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketogenic diet (KD) therapy
Study: 33772508
Drug: Control (adjustment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (adjustment of antiepileptic drugs)
Study: 35472141
Drug: Preoperative denosumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative denosumab, curettage and adjuvant local therapy (Arm B)
Study: 35472141
Drug: Curettage and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curettage and adjuvant local therapy (Arm A)
Study: 32155315
Drug: Deutetrabenazine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deutetrabenazine (25 mg)
Study: 32155315
Drug: Tetrabenazine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrabenazine (25 mg)
Study: 34427633
Drug: Ontamalimab 75
Normalized name: Ontamalimab
DrugBank: Ontamalimab (DB15298)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ontamalimab 75 mg every 4 weeks
Study: 32240350
Drug: 50% low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% low-dose images
Study: 32240350
Drug: Standard-dose images
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose images
Study: 32240350
Drug: Low-dose images
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose images
Study: 35491524
Drug: Exenatide twice-daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide twice-daily 10 μg with dapagliflozin-matched placebo
Study: 32046931
Drug: MET‐LIRA (MET-2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET‐LIRA (MET-2000 mg, LIRA 1.8 mg SC QD)
Study: 32046931
Drug: MET‐P (MET-2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET‐P (MET-2000 mg, Placebo QD)
Study: 35405248
Drug: Metformin (METF)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (METF) for 2 weeks
Study: 34050768
Drug: Intravenous posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous posaconazole (POS) prophylaxis for 7 days
Study: 34167827
Drug: 200-mg CTC
Normalized name: CTCE-0214
DrugBank: CTCE-0214 (DB05934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-mg CTC (equivalent to 112-mg celecoxib and 88-mg tramadol)
Study: 34167827
Drug: 100-mg tramadol
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-mg tramadol
Study: 34167827
Drug: 100-mg celecoxib
Normalized name: celecoxib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-mg celecoxib
Study: 34167827
Drug: 100-mg celecoxib
Normalized name: celecoxib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-mg celecoxib plus 100-mg tramadol
Study: 32744106
Drug: Anti-PD-1/PD-L1-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1/PD-L1-based therapy
Study: 34551104
Drug: Ad5-vectored COVID-19
Normalized name: covid-19, viral vector, non-replicating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5-vectored COVID-19 vaccine (5 × 10^10 viral particles)
Study: 34551104
Drug: Ad5-vectored COVID-19
Normalized name: covid-19, viral vector, non-replicating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5-vectored COVID-19 vaccine (single dose)
Study: 33979802
Drug: Pedometer-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pedometer-based intervention with weekly goals
Study: 32801651
Drug: JPI-289 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: JPI-289 35 mg
Study: 32801651
Drug: JPI-289 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: JPI-289 75 mg
Study: 32801651
Drug: JPI-289 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: JPI-289 150 mg
Study: 32801651
Drug: JPI-289 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: JPI-289 300 mg
Study: 32801651
Drug: JPI-289 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: JPI-289 450 mg
Study: 32801651
Drug: JPI-289 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: JPI-289 600 mg
Study: 32402554
Drug: Anti-VEGF treatment
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF treatment (overall)
Study: 32615110
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (80 mg/m2) with carboplatin AUC5 or AUC6 every 3 weeks (group 2)
Study: 32615110
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (80 mg/m2) with carboplatin AUC2 weekly (group 3)
Study: 32615110
Drug: 3-weekly chemotherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-weekly chemotherapy (carboplatin AUC5 or AUC6 and 175 mg/m2 intravenous paclitaxel) (group 1)
Study: 33888772
Drug: linagliptin/metformin 2.5/850
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin/metformin 2.5/850 mg twice daily (LM group)
Study: 33888772
Drug: metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin 850 mg twice daily (M group)
Study: 33308425
Drug: Cabotegravir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabotegravir plus rilpivirine long‐acting every 8 weeks (cabotegravir 600 mg plus rilpivirine 900 mg)
Study: 33308425
Drug: Cabotegravir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabotegravir plus rilpivirine long‐acting every 4 weeks (cabotegravir 400 mg plus rilpivirine 600 mg)
Study: 35773357
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Tadalafil 5 mg and Silodosin 8 mg
Study: 34177933
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy combined with pembrolizumab
Study: 34177933
Drug: Adjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemoradiotherapy and immunotherapy
Study: 32880094
Drug: Tailored work-related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored work-related support intervention (3 psychosocial meetings before treatment)
Study: 36244652
Drug: High-dose losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose losartan (150 mg/d)
Study: 36244652
Drug: Low-dose losartan
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose losartan (50 mg/d)
Study: 33419660
Drug: Treatment Initiation
Normalized name: Otezla 10mg-20mg 28-Day Treatment Initiation Pack Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Initiation Program
Study: 35659791
Drug: Ultraviolet-C (UV-C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultraviolet-C (UV-C) light treatment with a room decontamination device
Study: 32453759
Drug: dezocine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: dezocine (1 mg/kg) with sufentanil (1.3 μg/kg)
Study: 32453759
Drug: sufentanil (2.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: sufentanil (2.3 μg/kg)
Study: 35987809
Drug: Nutritional supplements,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements, protein‐rich, high‐fiber diet, care by a professional nutritionist
Study: 39037762
Drug: Preoperative statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative statin therapy
Study: 36075592
Drug: Calcitriol soft
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol soft capsules (0.25 μg each time, twice a day for 12 weeks).
Study: 33878192
Drug: Transdermal CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal CO2 gel
Study: 33878192
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (ultrasound gel)
Study: 36202236
Drug: COVID‐19 Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID‐19 Vaccine Message
Study: 34479797
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D supplementation (400-1600 IU/d)
Study: 35510562
Drug: Treatment (vaccine)
Normalized name: Hongo Killer Treatment
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (vaccine)
Study: 35742279
Drug: Online group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online group (n = 19) - 40‐min trunk stabilization exercise sessions twice a week for six weeks via ZOOM
Study: 34110614
Drug: 25 1-mg
Normalized name: Folplex 2.2 MG / 1 MG / 25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 1-mg OM slow-release minitablets
Study: 34110614
Drug: 25 1-mg
Normalized name: Folplex 2.2 MG / 1 MG / 25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 1-mg OM fast-release minitablets
Study: 34110614
Drug: 25-mg OM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-mg OM matrix MR tablet
Study: 34237987
Drug: Traditional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatments (non-surgical group)
Study: 32867832
Drug: Parent Child
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent Child Interaction Therapy ‐ Toddler
Study: 32556730
Drug: Haemoblock (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemoblock (15 ml retromuscularly and 15 ml subcutaneously)
Study: 35518935
Drug: Hydrocortisone dose
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone dose of 0.2-0.3 mg/kg/day
Study: 35518935
Drug: Hydrocortisone dose
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone dose of 0.4-0.6 mg/kg/day
Study: 34732432
Drug: Anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy (62 patients)
Study: 34732432
Drug: Non-anticoagulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-anticoagulation treatment (446 patients)
Study: 34732432
Drug: Preoperative anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative anticoagulation therapy
Study: 35189937
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (iCBT) consisting of 14 teleconference sessions with the child and parents, supported by an app for symptom assessment and wristband monitoring.
Study: 35189937
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list control group receiving treatment after a 16-week waiting period.
Study: 34076179
Drug: 25% oral
Normalized name: glucose 25% oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% oral glucose
Study: 34076179
Drug: 25% oral
Normalized name: glucose 25% oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% oral glucose combined with non-nutritive sucking
Study: 34196852
Drug: Povidone-iodine irrigation
Normalized name: povidone-iodine Irrigation Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Povidone-iodine irrigation of oral cavity for 3 min before operation
Study: 34196852
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gluconate irrigation of oral cavity for 3 min before operation
Study: 33512412
Drug: Response-adapted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response-adapted therapy including 4 cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide with involved-field radiation therapy (RT)
Study: 33512412
Drug: Response-adapted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response-adapted therapy including 4 cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide without involved-field radiation therapy (RT)
Study: 33512412
Drug: Additional chemotherapy
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional chemotherapy with dexamethasone, etoposide, cisplatin, and cytarabine for patients with slow early response
Study: 34990581
Drug: Higher-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose edoxaban regimen (HDER) 60 mg/reduced 30 mg
Study: 34990581
Drug: Lower-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose edoxaban regimen (LDER) 30 mg/reduced 15 mg
Study: 35221703
Drug: Bilastine (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilastine (standard dose)
Study: 35221703
Drug: Fexofenadine (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine (standard dose)
Study: 35221703
Drug: Levocetirizine (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine (standard dose)
Study: 35221703
Drug: Bilastine (up-dosing)
Normalized name: Q-Up
DrugBank: Bilastine (DB11591)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Bilastine (up-dosing)
Study: 35221703
Drug: Fexofenadine (up-dosing)
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine (up-dosing)
Study: 35221703
Drug: Levocetirizine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine + Hydroxyzine (combination)
Study: 33954789
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic Acid (ZA) with calcium and vitamin D; 5 infusions (0.025 mg/kg at months 0 and 3, 0.05 mg/kg at months 6, 12, and 18)
Study: 34970330
Drug: Aerosolized glucocorticoid
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized glucocorticoid combined with bronchodilator
Study: 36278221
Drug: H2-O2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-O2 group (inhaled H2-O2 mixture 66% H2/33% O2)
Study: 36278221
Drug: Air group
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air group (inhaled placebo air)
Study: 36334697
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D administration
Study: 32046418
Drug: Single-dose secnidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose secnidazole 2 g
Study: 34055971
Drug: Nomogram based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomogram based on predictive variables (age, site, grade, tumor size, histology, stage, use of surgery, radiotherapy, or chemotherapy)
Study: 33422811
Drug: Non-metformin users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-metformin users
Study: 36320143
Drug: Low-dose temsirolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose temsirolimus (0.1 mg/mL)
Study: 36320143
Drug: High-dose temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: High-dose temsirolimus (0.4 mg/mL)
Study: 36320143
Drug: Temsirolimus (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (combined low and high dose)
Study: 35470243
Drug: G‐POEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐POEM
Study: 34688948
Drug: T-cell receptor
Normalized name: T-cell receptor marker
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-cell receptor beta chain (TCRβ) features in COVID-19 patients
Study: 36401364
Drug: Autologous platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet-rich gel (APRG)
Study: 33598778
Drug: 0.8% hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8% hyaluronic acid gel + open flap debridement (OFD)
Study: 32176093
Drug: Pharyngeal electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharyngeal electrical stimulation (PES) treatment on 3 consecutive days in addition to best supportive care
Study: 32176093
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment on 3 consecutive days in addition to best supportive care
Study: 32585837
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein isolate + bioactives (WPI + BIO) capsules containing omega‐3 fatty acids, rutin, and curcumin
Study: 32585837
Drug: Carbohydrate +
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate + placebo capsules (CHO)
Study: 35671100
Drug: Intralymphatic immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralymphatic immunotherapy (ILIT) with ALK Alutard Birch and Grass 1000 SQ‐U, three intralymphatic injections with one-month intervals
Study: 33979488
Drug: Tezepelumab (210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab (210 mg) every 4 weeks for 52 weeks
Study: 33979488
Drug: Tezepelumab (210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab (210 mg)
Study: 34813673
Drug: Cenobamate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate (200 mg/day, median modal dose)
Study: 34813673
Drug: Cenobamate (≥100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate (≥100 mg/day)
Study: 32445670
Drug: Subcutaneous C1‐INH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous C1‐INH (40 IU/kg or 60 IU/kg) administered twice weekly for 52 to 140 weeks
Study: 36075589
Drug: Xingnao Kaiqiao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xingnao Kaiqiao acupuncture in addition to rt-PA intravenous thrombolysis
Study: 36075589
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication group (rt-PA intravenous thrombolysis only)
Study: 33284201
Drug: Early commencement
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early commencement of parenteral nutrition immediately after birth
Study: 33284201
Drug: Commencement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commencement of parenteral nutrition within 24 hours of admission
Study: 33284201
Drug: Delaying parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delaying parenteral nutrition to day 8 of admission
Study: 33284201
Drug: Very high
Normalized name: Very high density lipoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very high doses of amino acids (>3.5 g/kg/day) immediately after birth
Study: 33284201
Drug: Commencing parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commencing parenteral nutrition on the first day of life
Study: 33284201
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition after 72 hours if enteral feeds are not tolerated
Study: 33284201
Drug: Avoiding parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoiding parenteral nutrition within 24 hours of admission
Study: 32502443
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg) plus Bevacizumab (15 mg/kg) every 3 weeks
Study: 35536730
Drug: Intraoperative pectoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative pectoral nerve block (PECS) with 10 ml of 0.5% bupivacaine
Study: 35536730
Drug: Ultrasound guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided thoracic paravertebral block (TPV) with 25 ml of 0.25% bupivacaine at T3 level
Study: 33715994
Drug: Mannitol 400
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol 400 mg BID
Study: 36731588
Drug: Adalimumab (ADA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (ADA) treatment
Study: 35553959
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment for three days
Study: 32899094
Drug: Ropivacaine 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.125% + dexmedetomidine 0.5 μg/mL (RD1 group)
Study: 32899094
Drug: Ropivacaine 0.08%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.08% + dexmedetomidine 0.5 μg/mL (RD2 group)
Study: 32899094
Drug: Ropivacaine 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.125% + sufentanil 0.5 μg/mL (RS1 group)
Study: 32899094
Drug: Ropivacaine 0.08%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.08% + sufentanil 0.5 μg/mL (RS2 group)
Study: 32339499
Drug: Intravenous ghrelin
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ghrelin (3 mcg/kg loading dose followed by 16.9 ng/kg/min infusion)
Study: 32339499
Drug: Oral ghrelin
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ghrelin receptor blocker (PF-5190457)
Study: 33546069
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 μg/kg 5 minutes after anesthesia induction
Study: 33473242
Drug: Commiphora molmol
Normalized name: Commiphora molmol resin
DrugBank: Myrrh (DB11605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commiphora molmol (myrrh) mouthwash used twice a day for 7 days
Study: 33473242
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline mouthwash used twice a day for 7 days
Study: 36088783
Drug: Advice in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice in combination with blood flow restriction training (BFRT)